Analyst consensus rating

Anika Therapeutics Analyst Rating: Strong Buy

Direct answer

Anika Therapeutics's consensus rating is Strong Buy.

2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.00.
Forecast evidence checked November 22, 2026.

Get free Anika Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$13.23
Average price target
$20.00
High price target
$23.00
Low price target
$17.00
Low target gap
+28.5%
Target upside
+51.2%
High target gap
+73.8%
Target range width
45.4%
Consensus rating
Strong Buy
Analysts
2
Evidence date
November 22, 2026
Valid through
November 29, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Anika Therapeutics?

Anika Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $20.00.

How far are Anika Therapeutics's low and high targets from the recorded price?

The low target implies +28.5%, while the high target implies +73.8%.

How many analysts are included in Anika Therapeutics's consensus?

The verified consensus includes 2 analysts.

How is Anika Therapeutics's target upside or downside calculated?

The average target of $20.00 is divided by the recorded price of $13.23, then one is subtracted to produce +51.2%. This does not guarantee a future return.

When was Anika Therapeutics's analyst forecast verified?

The data was verified on 2026-11-22. The dataset is valid through 2026-11-29.